We experienced a pancreatic cancer patient whose muscle cramp arose by using S-1 was improved by the administration of a Kampo formulation Goshajinkigan (GJG).
Eighty-year-old female was diagnosed as having unresectable pancreatic cancer and then chemotherapy with S-1 and gemcitabine was initiated. After 4th course, gemcitabine had been discontinued by the toxicity, and then single administration for two weeks of a dose of 80 mg of S-1 was continued every three weeks. She often experienced muscle cramp at low legs, and she visited the emergency room with complaint of gait disturbance due to worse of muscle cramps. Her biochemical study showed almost normal electrolytes levels. Then a Kampo formulation Shakuyaku-kanzo-to (SKT), which was thought to be rapid-acting for these symptoms, was administered because of her sustained marked symptoms. No effect of SKT on these symptoms was observed; therefore, GJG was selected by Kampo medicine physician in combination with her complaints and body status. The administration of GJG was started 2.5 g once a day and then dose escalation was scheduled because it might induce gastrointestinal disorders. Since dose was escalated 5 g twice a day 2 weeks after initiation, incidence of muscle cramp was reduced three times a week. After 7 weeks, symptoms were disappeared. At this moment, she can continue the chemotherapy with S-1 under control of adverse event by the administration of 5 g of GJG twice a day.
Background: The objective of this retrospective study was to clarify prognostic factors in pancreatic cancer patients treated with curative resection followed by adjuvant chemotherapy with S-1. Methods: Both overall survival (OS) and recurrence-free survival (RFS) were examined in 76 pancreatic cancer patients who underwent curative surgery and received adjuvant chemotherapy with S-1 after surgery between 2007 and 2014. Results: When the length of OS was evaluated according to the log-rank test, significant differences were observed in the pathological tumor size. In addition, univariate and multivariate Cox’s proportional hazards analyses demonstrated that the pathological tumor size was the only significant independent prognostic factor for both OS and RFS. The 5-year OS was 0% in the pathological tumor size ≥ 60 mm group and 30.4% in the pathological tumor size < 60 mm group (p=0.010). Moreover, similar results were observed for recurrence-free survival (p=0.008). Conclusions: The pathological tumor size is the most important prognostic factor for OS and RFS in patients with pancreatic cancer treated with curative resection followed by adjuvant chemotherapy with S-1. The present results suggest that adjuvant chemotherapy with S-1 is not sufficient, especially in patients with relevant risk factors.
Background: The benefit of resecting recurrent tumor after curative esophagectomy for esophageal cancer remains unclear, especially when it requires resection of multiple visceral organs. Case presentation: A 56-year-old male patient with previous history of surgical treatment for esophageal achalasia 21 years before was referred to our hospital for treatment of lower thoracic esophageal cancer. He underwent a thoracoscopic esophagectomy and laparoscopic gastric mobilization with curative intent. Nine months after the operation, abdominal computed tomography revealed an intraperitoneal abscess formed along the distal part of the splenic artery. Percutaneous drainage of the abscess and cytological examination diagnosed the tumor as recurrent squamous cell carcinoma from the esophageal cancer. For symptom alleviation and potential cure, the recurrent nodule together with the pancreatic tail, spleen, and left adrenal grand were resected. The pathological examination confirmed recurrent esophageal cancer at the splenic hilar. Three years later, the patient remains disease free. Conclusion: We experienced a case with metastatic recurrence of lower thoracic esophageal cancer to the hilar of the spleen. When tumor recurrence of esophageal cancer is solitary, an aggressive surgical treatment with multiple-organ resection potentially results in long-term disease-free survival in selected patients.
Reports suggest that jejunal pouch interposition (JPI) after proximal gastrectomy is superior in terms of food intake volume and prevention of reflux esophagitis early after surgery. However, the long-term results and late complications of the procedure are not well known. This case report describes an excessive pouch dilatation necessitating surgical intervention as a late complication of JPI. The patient was a 62-year-old woman with early gastric cancer who underwent proximal gastrectomy. Gastrointestinal continuity was restored with JPI. The patient’s postoperative course was uneventful and follow-up imaging studies showed no signs of tumor recurrence. However, the patient gradually started to experience difficulty eating food and complained of postprandial nausea and vomiting. Contrast radiography of the upper gastrointestinal tract revealed a dilated jejunal pouch, which eventually required surgical intervention. The jejunal pouch and remnant stomach were resected, followed by Roux-en-Y reconstruction. The postoperative course was uneventful and the symptoms subsided. The present case highlights the importance of a clinical study focusing on the long-term results of this surgical procedure.
Background and purpose: This study aimed to evaluate whether we can predict tumor response prior to neoadjuvant chemoradiotherapy (NACR) with concurrent radiofrequency (RF) thermal therapy for rectal cancer. Material and Methods: This study included 80 patients with primary rectal adenocarcinoma localized in the rectum (up to 12 cm from the anal verge) and who received NACR intensity-modulated radiotherapy (IMRT) once daily 5 times/week, 50 Gy delivered to the planning target volume (PTV) in 25 fractions, capecitabine 1700 mg/m2 per day for 5 days per week, and thermic treatment (once a week for 5 weeks with 50 min irradiation). In order to further minimize RF-related complications, we used an initial time of 0 min for the time at which an output limiting symptom occurred as a predicted initial RF output (IRO) and compared this to the tumor response and target volumes (TVs) as defined by computed tomography (CT), magnetic resonance imaging (MRI), and/or 18F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) findings. A receiver operating characteristic (ROC) curve analysis was used in this study to identify the best-fitted cut-off value for predicted initial radiofrequency output (IRO) and TVs. Results: Gross tumor volume (GTV) correlated significantly with tumor stages, lymph node stages, and pretreatment TNM stages, but not clinical tumor volume (CTV) and PTV. GTV was a better imaging parameter than CTV and PTV for prediction of treatment response in this modality. Patients with predicted IRO ≥ 669.4 Watt, increased body temperature by RF thermal therapy and had a GTV ≤ 31.2 cm3 showed a good indication for this modality. Conclusions: We will be able to select rectal cancer patient prior treatment who respond to chemoradiation therapy with concurrent thermal therapy.
April 03, 2017 There had been a system trouble from April 1, 2017, 13:24 to April 2, 2017, 16:07(JST) (April 1, 2017, 04:24 to April 2, 2017, 07:07(UTC)) .The service has been back to normal.We apologize for any inconvenience this may cause you.
May 18, 2016 We have released “J-STAGE BETA site”.
May 01, 2015 Please note the "spoofing mail" that pretends to be J-STAGE.